Daily Pharma Scoop: Geron’s growth potential, Ipsen’s Xarmelo approval, GSK Ellipta approved
- Geron is a true binary event for next year.
- Ipsen’s Xarmelo approved in EU for carcinoid syndrome diarrhea.
- GlaxoSmithKline's Trelegy Ellipta approved for COPD.
Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok Dutta, is writing a daily scoop of all sorts of news, catalysts, ratings, and other actionable details for its watch list stocks (and the rest of the healthcare universe). The watch list is available to Total Pharma Tracker subscribers. Some sections, like the catalyst data, abstract selections, AdComm coverages, Buy/Sell summaries etc are also available to subscribers only. This is an abridged version; for the entire Pharma Scoop, please subscribe to our Marketplace service.
Our daily analysis of a stock with a major event/upside: Geron’s potential with Imetelstat and its agonizingly slow progress towards the market
The full unabridged post can be accessed, on SeekingAlpha Marketplace.